Turnstone Biologics (NASDAQ:TSBX) Given New $3.75 Price Target at Piper Sandler

Turnstone Biologics (NASDAQ:TSBX) had its target price lowered by Piper Sandler from $20.00 to $3.75 in a research note issued to investors on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, Bank of America reduced their target price on shares of Turnstone Biologics from $12.00 to $10.00 and set a buy rating on the stock in a report on Monday.

Turnstone Biologics Price Performance

TSBX stock opened at $0.77 on Monday. The company has a market capitalization of $17.81 million and a price-to-earnings ratio of -0.08. Turnstone Biologics has a 1-year low of $0.73 and a 1-year high of $12.16. The business has a 50 day simple moving average of $2.41 and a two-hundred day simple moving average of $2.77.

Turnstone Biologics (NASDAQ:TSBX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.08). Sell-side analysts anticipate that Turnstone Biologics will post -3.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Turnstone Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in TSBX. Kathleen S. Wright Associates Inc. purchased a new position in shares of Turnstone Biologics in the 1st quarter worth approximately $111,000. Zimmer Partners LP grew its holdings in Turnstone Biologics by 271.4% in the first quarter. Zimmer Partners LP now owns 179,026 shares of the company’s stock worth $469,000 after purchasing an additional 130,826 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Turnstone Biologics during the second quarter worth $31,000. Institutional investors own 52.51% of the company’s stock.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.